Overview
Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. The study will prospectively enroll 58 patients with benign and low-grade brain tumors who will undergo partial brain RT, with either conventionally fractionated or hypofractionated schedules. Subjects will receive MRI scans at baseline and 6 months. Given the role of the limbic system in key cognitive functions affected by RT, researchers have a particular interest in characterizing MRI changes in the limbic system and thalamus in relation to memory and related processes.
Specific Aims:
- To examine objective neurocognitive changes over time. The investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT.
- To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators specifically hypothesize that comapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT.
- To examine the relationship between MRI changes for key neuroanatomic structures identified in Aim 1 with objective neurocognitive testing. The investigators hypothesize that cognitive decline will be correlated with damage revealed by MRI to limbic and thalamic structures.
This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes.
Description
Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. This suggests that off-target RT, even at low doses, may have a negative cognitive impact by affecting neuroanatomic targets proximal or distal to the tumor. While constraints to minimize brain necrosis, ototoxicity, and optic neuropathy are well-established, RT dose tolerances for cognitive changes in key domains (memory, attention, executive function, and processing speed) that occur in RT-treated patients are poorly characterized. There is accumulating evidence that consideration of neuroanatomic targets could better explain cranial RT-mediated cognitive change. Additionally, a recent cooperative group phase III trial has shown that conformal avoidance of the hippocampus with whole brain RT can reduce cognitive impairment. Unfortunately, 60% of patients still had cognitive impairment at 6 months even with hippocampal avoidance, implying that other structures and networks are involved in cognitive deficits from RT and efforts to identify those structures are warranted. A major obstacle in the field has been difficulty identifying sites of off-target tissue damage that could impact cognition after RT. Given the role of the limbic system in key cognitive functions affected by RT, the investigators have a particular interest in characterizing changes in limbic system and thalamus in relation to memory and related processes.
The investigators plan to examine RT effects on neuroanatomic structures in the limbic system and thalamus as well as candidate structures identified systematically using magnetic resonance imaging (MRI). The investigators propose to prospectively enroll 58 patients with benign and low-grade brain tumors who will undergo partial brain RT, either conventionally fractionated or hypofractionated.
Neurocognitive testing will be obtained at baseline, 3, and 6 months after RT using a battery of tests to assess visual and verbal memory, attention, executive function, and processing speed. Brain MRI, including high resolution T1 images, diffusion tensor imaging (DTI), and resting functional MRI (fMRI) sequences, will be evaluated at baseline and 6 months after RT.
This pilot study will provide preliminary data to identify key areas impacted by RT that can be followed up in future research.
Aim 1: To examine objective neurocognitive changes over time. Based on prior data, the investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT. The investigators will evaluate neurocognitive testing changes using a composite global deficit z-score (primary endpoint) as well as z-score changes in cognitive domains of verbal and visual memory, attention, executive function and processing speed.
Aim 2: To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators hypothesize that a detailed brain tissue injury mapping of off-target RT doses from pre to post-RT and reconstructed structural and functional connectivity (DTI and fMRI) will provide data on the relationship between RT dose and MRI changes in specific structures. The investigators specifically hypothesize that co-mapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT.
Aim 3: To examine the relationship between MRI changes for key neuroanatomic structures with neurocognitive testing. The investigators hypothesize that RT will impact several neuronal networks sub-serving multiple cognitive domains and cognitive decline (Aim 2) will be correlated with damage revealed by MRI to limbic and thalamic structures (Aim 1). This approach will allow identification of brain structures most associated with domain-specific cognitive impairment.
There is critical need for well-designed longitudinal studies that examine the impact of RT on neuroanatomic structures. Many of the studies that evaluate cognition with RT do not take into account neuroanatomic dose distributions. Even within the literature that evaluates neuroanatomic targets, there has not been a systematic approach to evaluation of neuroanatomic targets by RT. This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes.
Eligibility
Inclusion Criteria:
- >18 years old patients with brain tumors including low grade gliomas, meningiomas, acoustic neuromas, pituitary adenomas, craniopharyngiomas, hemangiopericytomas, pineal tumors, and other benign or slow-growing brain tumors
- Pathologic diagnosis will be required for gliomas, but not for other tumor types (though it will be recorded if available)
- Within 3 months prior to registration, patients must have a post gadolinium contrast-enhanced three dimensional spoiled gradient (SPGR), magnetization-prepared rapid gradient echo (MP-RAGE), or turbo field echo (TFE) MRI scan and an axial T2/FLAIR sequence. To yield acceptable image quality with the smallest possible axial slice thickness, , the imaging protocol should include the standard brain tumor protocol sequences: long DTI, sagittal SPGR, and brainlab sequences, resting functional MRI or their equivalent.
- Patients will need to be planned to receive fractionated radiation therapy or stereotactic radiation therapy, either fractionated or single fraction (enrollment must occur prior to radiation therapy so that baseline neurocognitive evaluation can be done)
- Surgical excision and/or chemotherapy treatment prior to enrollment is allowed
- Concurrent chemotherapy with radiation is allowed
- Antiepileptic drugs use, seizures, steroids, anticholinergic medications will be recorded but patients will not be excluded
- Hydrocephalus will be recorded, but patients will not be excluded
Exclusion Criteria:
- Prior cranial radiation therapy
- Other active malignancy
- Contraindication to MRI imaging such as implanted metal devices or foreign bodies
- Contraindication to gadolinium contrast administration during MR imaging such as allergy or insufficient renal function
- Intractable seizures while on adequate anticonvulsant therapymore than 1 seizure per month for the past 2 months
- Life expectancy <6 months due to other severe comorbidity
- Due to limitations in our ability to test patients in languages other than English, patients will have to be English-speaking
- Diagnosis of pre-existing dementia (clinically significant as defined by a neurologist or other provider), neurodegenerative, or neuro-inflammatory conditions as made by an appropriate health care professional such as a neurologist
- Inability to participate in neuro-cognitive testing
- Significant aphasia leading to difficulty participating in neuro-cognitive testing